Compare Neurocrine Biosciences Inc (NBIX) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs United Microelectronics Corp — how do they compare? Neurocrine Biosciences Inc trades at $142.25 (market cap $14.36B), while United Microelectronics Corp trades at $22.89 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 4× Neurocrine Biosciences Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and United Microelectronics Corp for 42 Days on average.
| NBIX | UMC | |
|---|---|---|
Market Cap | $14.36B | $58.02B |
Volume | 1,237,180 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $185.50 | $28.02 |
52-Week Low | $123.10 | $7.02 |
Typical Hold Time | 23 Days | 42 Days |
Enterprise Value | $14.37B | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
UMC trades at $23.31, up 0.52% with a bullish technical signal despite mixed moving averages. The company shows strong profitability with 32.75% net margin and 21.03% ROE, though revenue growth has moderated from 2022 peaks. Recent earnings beats and a Zacks Strong Buy upgrade (September 17, 2026) highlight positive momentum, while cash flow turned positive in 2025 after two years of outflows.
The stock presents growth potential with expanding AI opportunities and strong 22/28nm demand, but faces risks from semiconductor cycle volatility and competitive pressures. Analyst consensus is mixed with 27% buy ratings versus 20% sell, suggesting cautious optimism amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
